1. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program
by Michael A. Pulsipher, Pintip Chitphakdithai, Brent R. Logan, Bronwen E. Shaw, John R. Wingard, Hillard M. Lazarus, Edmund K. Waller, Matthew Seftel, David F. Stroncek, Angela M. Lopez, Dipnarine Maharaj, Peiman Hematti, Paul V. O'Donnell, Alison W. Loren, Susan F. Leitman, Paolo Anderlini, Steven C. Goldstein, John E. Levine, Willis H. Navarro, John P. Miller, and Dennis L. Confer
Blood
Volume 121(1):
January 3, 2013
©2013 by American Society of Hematology

2. Donor blood counts at baseline, on the day of collection, and at postdonation follow-ups.
Donor blood counts at baseline, on the day of collection, and at postdonation follow-ups. (A) Donor white blood cell (WBC) counts. (B) Donor platelet counts. (C) Donor hemoglobin levels. Minimum, lower quartile, median, upper quartile, maximum; day 5 is the first day of apheresis; Pre and Post refer to the apheresis procedure.
Michael A. Pulsipher et al. Blood 2013;121:
©2013 by American Society of Hematology

3. Pain.
Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period, and after donation. (Skeletal pain represents pain in at least 1 of the following sites: back, bone, headache, hip, limb, joint, and neck.) The severity of skeletal pain is defined as the maximum grade among these pain sites. Day 2 is the second day of filgrastim; day 5 is the first day of apheresis. (B) Sites of pain among BM and PBSC donors on the day noted to have the highest severity of pain (1-2 days post-BM collection and day + 5 from start of G-CSF for PBSC).
Michael A. Pulsipher et al. Blood 2013;121:
©2013 by American Society of Hematology

4. Toxicities.
Toxicities. (A) Highest toxicity level of key symptoms (fever in the absence of signs of infection, fatigue, skin rash, local reactions, nausea, vomiting, anorexia, insomnia, dizziness, and syncope) experienced by BM and PBSC donors at baseline, during pericollection period, and after donation. (Day 2 is the second day of filgrastim; day 5 is the first day of apheresis.) (B) Toxicities among BM and PBSC donors on the day noted to have the highest level of toxicity (1-2 days post-BM collection and day + 5 from start of G-CSF for PBSC). (C) Common toxicities among BM and PBSC donors on the day noted to have the highest level of toxicity (1-2 days post-BM collection and day + 5 from start of G-CSF for PBSC), and at selected time points after donation.
Michael A. Pulsipher et al. Blood 2013;121:
©2013 by American Society of Hematology

5. Univariate probability of reported complete recovery from stem cell donation.
Michael A. Pulsipher et al. Blood 2013;121:
©2013 by American Society of Hematology